A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma
← catalyst calendarNCT06230224 · readout in 649 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
216actual
Sites
81
Countries
Argentina, Australia, Brazil +11
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-02-15 | actual | When the study began enrolling |
| Primary completion | 2028-05-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-05-29 | estimated | The whole study's end, after follow-up |
| First posted | 2024-01-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- B-Cell Non-Hodgkin Lymphoma (B-NHL)
Interventions
- Drug: Odronextamab — also filed as R1979
- Drug: Ifosfamide — also filed as Ifex
- Drug: Carboplatin — also filed as Paraplatin
- Drug: Etoposide — also filed as Etopophos
- Drug: Rituximab — also filed as Rituxan
- Drug: Dexamethasone — also filed as Decadron
- Drug: Cisplatin — also filed as Platinol
- Drug: Cytarabine — also filed as Cytosar-U
- Drug: Gemcitabine — also filed as Gemzar
Primary outcome
what the primary-completion date above is the date OFEvent-free survival (EFS) as assessed by independent central review (ICR)
measured Assessed up to 3 years
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed